Ms Cédriane de Boucard

Cédriane is a founder and senior partner of Disruptive Capital. She has a long-demonstrated history of working in the venture capital and private equity industry in corporate development and mergers & acquisitions (M&A). She holds an MA in Economics and a BA in Economics & Political Science, both from Cornell University (USA). She worked until 1999 as a restructuring and turnaround specialist with PriceWaterhouse in New York and Moscow. Cédriane then worked with a portfolio of early-stage tech companies with a venture capital firm, before raising a technology fund and spinning it out to what became Disruptive Capital Finance

Edmund Truell

Edi Truell has 30 years of financial services experience in private equity and debt markets. In 1998 he formed Duke Street Capital and was chairman of the British Venture Capital Association from 2001 to 2002. He is also a Trustee of The Truell Charitable Foundation and the Charles Darwin Foundation.

In 2010, Edi founded Disruptive Capital Finance, a private equity and venture capital firm specialising in investments in early venture, mid venture, and growth capital. Its investments include The Tungsten Corporation, IRX Therapeutics, Atlantic Superconnection, and Tantalum Corporation. He is founder and architect of the Pension Superfund.

Dr. David Brown

Dr Brown has 40 years experience in the pharmaceutical / biotechnology industry both in research and in senior executive roles. Named as co-inventor on the patent for Viagra and later as Global Head of Drug Discovery for Roche.

Dr Brown has a strong interest in entrepreneurialism. He coaches CEOs and  entrepreneurs at Centre for Entrepreneurial Learning at Cambridge University  Business School and he is an Angel Investor in high-technology start-up  companies. He co-founded Crescendo Biologics of which he is currently  interim Chair of the board.

He is a Trustee of  Antibiotic Research UK